LB Pharmaceuticals (LBRX) news

Priced: LBBW EUR 750M 2Y covered MS+7

LB Pharmaceuticals reports inducement grants to new employee under Nasdaq listing rule 5635(C)(4)

LB Pharmaceuticals has disclosed inducement grants awarded to a new employee in accordance with Nasdaq Listing Rule 5635(C)(4). The rule permits listed companies to issue equity-based compensation to new employees without shareholder approval, provided the grants are made in connection with the…

LB Pharmaceuticals Inc: Canaccord Genuity initiates coverage with buy rating; target price $65

Canaccord Genuity has initiated coverage of LB Pharmaceuticals Inc with a "buy" rating and target price of $65 per share. The firm cited the company’s strong product pipeline, recent regulatory approvals, and favorable market positioning as key factors supporting its recommendation. Analysts…

LPC: Announces initial public offering of 3,750,000 ordinary shares - SEC filing

Louisiana-Pacific Corporation (LPC) has filed with the U.S. Securities and Exchange Commission (SEC) to offer 3,750,000 ordinary shares in an initial public offering. The filing marks the company’s formal step toward a public listing, though details such as pricing range, expected proceeds, and…

LB Pharmaceuticals Inc: Needham initiates coverage with buy rating; target price $68

LB Pharmaceuticals Inc (NASDAQ:LBRX) has recently drawn attention from analysts at Needham, who have initiated coverage of the stock with a "Buy" rating and target price . This recommendation aligns with broader analyst sentiment, as several firms have maintained positive outlooks on the company in…